SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity

Journal of Cellular Physiology

Volumn 210, Issue 1, 2007, Pages 161-166

  Jin, Ming Dai ^a   Zhi, Yan Wang ^a   Dao, Chun Sun ^a   Ru, Xian Lin ^a   Sheng, Qi Wang ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PROTEIN P73; PROTEIN SIRT1; SIRTUIN;

ACETYLATION; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEACETYLATION; FUNCTIONAL PROTEOMICS; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

ACETYLATION; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DOWN-REGULATION; ENZYME INHIBITORS; GAMMA RAYS; GENES, REPORTER; HELA CELLS; HUMANS; LUCIFERASES; NIACINAMIDE; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROMOTER REGIONS (GENETICS); PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; SIRTUINS; STILBENES; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 33845396682     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20831     Document Type: Article

References (35)

1. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. 2001. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 98:15113-15118.
2. Chalk AM, Sonnhammer EL. 2002. Computational antisense oligo prediction with a neural network model. Bioinformatics 18:1567-1575.
3. Chen WY, Wang DH, Yen RC, luo J, Gu W, Bavlin SB. 2005. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123:437-448.
4. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF. 2003. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 100:10794-10799.
5. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M. 2002. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes molecular. Cell 9:175-186.
6. Dobbelstein M, Wienzek S, Konig C, Roth J. 1999. Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18:2101-2106.
7. Dulic V, Kaufmann WK, Lees SJ, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023.
8. Ford J, Jiang M, Milner J. 2005. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65:10457-10463.
9. Frye RA. 2000. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 273:793-798.
10. Gottlieb T, Oren M. 1996. p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102.
11. Guarente L. 2000. Sir2links chromatin silencing, metabolism, and aging. Genes Dev 14:1021-1026.
12. Guarente L. 2001. Sir2and aging - The exception that proves the rule. Trends Genet 17:391-392.
13. Haupt Y, Maya R, Kazaz A. 1997. Oren M. Mdm2 promotes the rapid degradation of p53 Nature 387:296-299.
14. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196.
15. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. 2003. Chemosensitivity linked to p73 function. Cancer Cell 3:403-410.
16. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation, EMBO J 21:6236-6245.
17. Jost CA, Marin MC, Kaelin WG. 1997. p73 is a human p53-related protein that can induce apoptosis. Nature 389:191-194.
18. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J, Valent A, Minty A, Chalon P, Lelias J, Dumont X, Ferrara P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
19. Ko LJ, Prives C. 1996. p53: Puzzle and paradigm. Genes Dev 10:1054-1072.
20. Landry J, Slama JT, Sternglanz R. 2000. Role of NAD+ in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun 278:685-690.
21. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG, Kouzarides T. 2002. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21:2383-2396.
22. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
23. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. 2001. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148.
24. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
25. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh J-K, Zhong S, Campargue I, Crook T, Lu X. 2001. ASPP Proteins Specifically Stimulate the Apoptotic Function of p53. Mol Cell 8:781-794.
26. Shore D. 2000. The Sir2protein family: A novel deacetylase for gene silencing and more. Proc Natl Acad Sci USA 97:14030-14032.
27. Sinclair DA. 2002. Paradigms and pitfalls of yeast longevity research. Mech Ageing Dev 123:857-867.
28. Urist M, Tanaka T, Poyurovsky MV, Prives C. 2004. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18:3041-3054.
29. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159.
30. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Fryeand RA, Mayo MW. 2004. Modulation of NF-KB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-2380.
31. Zauberman A, Lupo A, Oren M. 1995. Identification of p53 target genes through immune selection of genomic DNA: The cyclin G gene contains two distinct p53 binding sites. Oncogene 10:2361-2366.
32. Zeng X, Li X, Miller A, Yuan Z, Yuan W, Kwok RP, Goodman R, Lu H. 2000. The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol Cell Biol 20:1299-1310.
33. Zeng X, Lee H, Zhang Q, Lu H. 2001. p300 does not require its acetylase activity to stimulate p73 function. J Biol Chem 276:48-52.
34. Zhao LY, Liu Y, Bertos NR, Yang X-J, Liao D. 2003. PCAF is a coactivator for p73-mediated transactivation. Oncogene 22:8316-8329.
35. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31:3406-3415.